# A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

> **NCT03019289** · PHASE1 · COMPLETED · sponsor: **Prilenia** · enrollment: 23 (actual)

## Conditions studied

- Health Volunteers, Huntington Disease

## Interventions

- **DRUG:** pridopidine (90 mg)

## Key facts

- **NCT ID:** NCT03019289
- **Lead sponsor:** Prilenia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-19
- **Primary completion:** 2018-02-09
- **Final completion:** 2018-02-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019289, "A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03019289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*